[Regenerative therapy in cardiology].
The aim of regenerative medicine is the reconstitution of the physiological structure of critically damaged organs. Bone marrow derived stem cells (BMDCs) show promising therapeutic potential. BMDCs are already used in oncology and are ideally suited for regenerative medicine due to their regenerative potential and safety profile. A variety of cells have been contemplated in cardiology, and there is emerging preclinical and clinical data on the feasibility and safety of different cell lines in the setting of acute myocardial infarction and chronic heart failure. In this review, the various concepts and cells will be discussed in further detail.
Chatterjee
T
T
Abteilung für Kardiologie, Universitätsklinikum Rostock (D) und Herzzentrum Hirslanden Zentralschweiz, Klinik St. Anna, Luzern, Germany.
Ortak
J
J
Akin
I
I
Adolph
E
E
Kleinfeldt
T
T
Kische
S
S
Nienaber
C A
CA
Ince
H
H
D032761:Animal Experimentation; D000818:Animals; D035843:Biomedical Research; D002309:Cardiology / Q000639:trends*; D002908:Chronic Disease; D004195:Disease Models, Animal; D053595:Embryonic Stem Cells / Q000502:physiology / Q000637:transplantation; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006331:Heart Diseases / Q000628:therapy*; D006333:Heart Failure / Q000628:therapy; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D015337:Multicenter Studies as Topic; D039902:Multipotent Stem Cells / Q000502:physiology / Q000637:transplantation*; D032446:Myoblasts / Q000502:physiology / Q000637:transplantation; D009203:Myocardial Infarction / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D044968:Regenerative Medicine; D033581:Stem Cell Transplantation; D013997:Time Factors; D014182:Transplantation, Autologous
D016179:Granulocyte Colony-Stimulating Factor